2016-07-07 13:48:25 UTC

What Does the Future Hold for Upper GI Disorders?

July 13, 2016

Join your colleagues at the first annual AGA Drug Development Conference Oct. 27 and 28.

Join colleagues in research, practice, industry, policy and patient advocacy to discuss where we are now and what the future holds for the diagnosis and treatment of upper GI disorders.

The first annual AGA Drug Development Conference: Clinical Endpoints in Upper GI Disorders, organized by the AGA Center for Diagnostics and Therapeutics (CDT), will take place Oct. 27 and 28 in Washington, DC, and will focus on the critical need to facilitate development of new medicines and biomarkers for upper GI disorders.The prevalence of GERD, eosinophilic esophagitis, gastroparesis and functional dyspepsia are growing but therapeutic options remain limited.

Learn from the leading experts in the field and lend your voice to the conversation about the challenges and potential solutions in clinical trial design, endpoint evaluation, and what this ultimately means for new diagnostics and therapeutics for upper GI disorders.

Register by Sep. 16 to take advantage of early registration discounts. To learn more, visit ddc.gastro.org.


More on Barrett's Esophagus

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

How to Talk with Your Patients About PPIs and Cognitive Decline

Feb. 22, 2018

More information clearing concerns about the use of proton pump inhibitors (PPIs).